Oncology Corporate Profile
Seattle Genetics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease.
|Abraxane®||paclitaxel nanoparticle albumin-bound||Abraxane® is a microtubule inhibitor indicated for the treatment of:Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.|
•Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
•Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.
|Adcetris®||brentuximab vedotin||Adcetris® is a CD30-directed antibody-drug conjugate indicated for treatment of patients with:|
•Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.
•Classical HL at high risk of relapse or progression as post-auto-HSCT consolidation.
•Systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen (1.3). Accelerated approval was granted for the sALCL indication based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
View additional information on commercial products here »
|Brand / Product||Class||Area of Study||Phase||Partnership|
|brentuximab vedotin||antibody drug conjugate (anti-CD30)||2nd line Hodgkin's Lymphoma||III|
|Vadastuximab talirine / SGN-CD33A||antibody drug conjugate (anti-CD33)||Acute Myelogenous Leukemia (AML)||III|
|brentuximab vedotin||antibody drug conjugate (anti-CD30)||Cutaneous T-cell Lymphoma (CTCL)||III|
|brentuximab vedotin||antibody drug conjugate (anti-CD30)||Hodgkin's Lymphoma||III|
|Denintuzumab mafodotin / SGN-CD19A||antibody drug conjugate (anti-CD19)||1st line diffuse large B-cell lymphoma (DLBCL)||II|
|Denintuzumab mafodotin / SGN-CD19A||antibody drug conjugate (anti-CD19)||2nd line diffuse large B-cell lymphoma (DLBCL)||II|
|brentuximab vedotin||antibody drug conjugate (anti-CD30)||CD30-expressing mature T-cell Lymphoma (MTCL)||II|
|SGN-CD19A||antibody drug conjugate (anti-CD19)||Diffuse large B-cell Lymphoma (DLBCL)||II|
|Vadastuximab talirine / SGN-CD33A||antibody drug conjugate (anti-CD33)||Myelodysplastic Syndrome (MDS)||II|
|brentuximab vedotin||antibody drug conjugate (anti-CD30)||Relapsed CD30-expressing diffuse large B-cell lymphoma (DLBCL)||II|
|brentuximab vedotin||antibody drug conjugate (anti-CD30)||Relapsed Non-Hodgkin's Lymphoma (NHL)||II|
|SGN-CD19A||antibody drug conjugate (anti-CD19)||Acute Lymphocytic Leukemia (ALL)||I|
|SGN-CD19B||antibody drug conjugate (anti-CD123)||Acute Myelogenous Leukemia (AML)||I|
|SGN-CD19B||antibody drug conjugate (anti-CD19)||B-cell Non-Hodgkin's Lymphoma (NHL)||I|
|ASG-15ME||antibody drug conjugate (ADC)||Bladder cancer||I||Astellas|
|SGN-LIV1A||antibody drug conjugate (ADC)||Breast cancer||I|
|SGN-LIV1A||antibody-drug conjugate (ADC)||Breast cancer||I|
|Enfortumab vedotin / ASG-22ME||antibody drug conjugate (anti-Nectin-4)||Metastatic Urothelial cancer||I||Astellas|
|SGN-CD48A||antibody drug conjugate (anti-CD30)||Multiple Myeloma||I|
|SGN-CD352A||antibody drug conjugate (anti-CD30)||Multiple Myeloma||I|
|SGN-CD19A||antibody drug conjugate (anti-CD19)||Non-Hodgkin's Lymphoma (NHL)||I|
|SGN-CD70A||antibody drug conjugate (anti-CD70)||Non-Hodgkin's Lymphoma (NHL)||I|
|SEA-CD40||CD40 inhibitor||Various cancer types||I|
View additional information on product candidates here »
11/8/2016 11:27 am
(BioMed Reports) Nov 8, 2016 - ECHELON-2 trial represents key component of late-stage clinical development strategy to establish Adcetris as foundation of care for CD30-expressing lymphomas; data from ECHELON-2 phase 3 trial expected in 2017 to 2018 timeframe.
10/17/2016 11:31 am
(ACCC) Oct 14, 2016 - The Association of Community Cancer Centers (ACCC) congratulates current President Jennie R. Crews, MD, MMM, FACP, on her new position as medical director for Seattle Cancer Care Alliance (SCCA).
10/7/2016 11:00 am
(Yahoo! Finance) Oct 7, 2016 - Seattle Genetics, Inc. and Agensys, an affiliate of Astellas, today presented updated clinical data for enfortumab vedotin (ASG-22ME) and ASG-15ME at the European Society for Medical Oncology (ESMO) Congress being held October 7-11, 2016 in Copenhagen, Denmark.
8/17/2016 11:24 am
(Seattle Times) Aug 16, 2016 - About 140 cancer patients may have been exposed to tuberculosis by a health-care worker who was diagnosed with an active case of the disease, officials with the University of Washington Medical Center and the Seattle Cancer Care Alliance said Tuesday.
8/1/2016 11:52 am
(European Pharmaceutical Review) Aug 1, 2016 - Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc. announced that the Phase 3 ALCANZA clinical trial evaluating ADCETRIS (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL) met its primary endpoint, demonstrating a highly statistically significant improvement in the rate of objective response lasting at least four months (ORR4).
8/1/2016 07:16 am
(Takeda) Aug 1, 2016 - Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc. today announced that the Phase 3 ALCANZA clinical trial evaluating ADCETRIS (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL) met its primary endpoint, demonstrating a highly statistically significant improvement in the rate of objective response lasting at least four months (ORR4).
7/8/2016 11:15 am
(Puget Sound Business Journal) July 7, 2016 - The Seattle Cancer Care Alliance has agreed to pay $250,000 to settle a U.S. Justice Department investigation relating to the loss of more than 96,000 pills between 2011 and 2013.
6/13/2016 12:00 pm
(The Business Journals) June 11, 2016 - Phase 1 clinical data featured in press program and oral presentation demonstrate 76 percent objective response rate, including a 41 percent complete remission rate, in newly diagnosed AML patients treated with 33A combination therapy; data support recently initiated phase 3 CASCADE study evaluating 33A in combination with hypomethylating agents in AML patients.
6/6/2016 05:35 pm
(TMCnet.com) June 6, 2016 - Seattle Genetics, Inc. and Astellas Pharma Inc. today presented first clinical data for ASG-15ME and enfortumab vedotin (ASG-22ME) at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting being held June 3-7, 2016, in Chicago, IL.
6/3/2016 02:01 pm
(ASCO Annual Meeting) June 3, 2016 - A biosimilar trastuzumab antibody (MYL-1401O) is comparable in efficacy and safety to the FDA-approved targeted breast cancer drug trastuzumab (Herceptin) in women with HER2-positive advanced breast cancer, according to a randomized phase III study.
6/3/2016 01:28 pm
(Seattle Children's) June 2, 2016 - Seattle Children's announced today that 39 of 42 patients treated in a Phase 1 clinical trial using genetically reprogrammed T cells to treat relapsed or refractory acute lymphoblastic leukemia (ALL) have achieved complete remission, showing no detectable leukemia cells in the most sensitive tests.
5/25/2016 11:11 am
(Seattle Genetics) May 25, 2016 - Seattle Genetics, Inc. today announced initiation of a pivotal phase 3 clinical trial, called CASCADE, evaluating vadastuximab talirine (SGN-CD33A; 33A) in combination with azacitidine (Vidaza) or decitabine (Dacogen) in older patients with newly diagnosed acute myeloid leukemia (AML).
4/18/2016 11:23 am
(Morningstar) Apr 17, 2016 - Innovative research demonstrates Seattle Genetics’ leadership in empowered antibodies.
4/14/2016 12:03 pm
(Morningstar/Dow Jones Newswires) Apr 14, 2016 - The U.S. Food and Drug Administration has accepted Bristol-Myers Squibb Co.’s supplemental biologics license application to expand the use of its cancer drug Opdivo to patients who are facing difficult-to-treat variations of Hodgkin lymphoma, the pharmaceutical company said Thursday.
4/14/2016 11:01 am
(MedUni Vienna [Austria]) Apr 14, 2016 - Mutations in the TP53 gene can have harmful consequences.
3/18/2016 10:02 am
(Kaiser Health News) Mar 18, 2016 - Aetna and Cigna inked deals in early February with drugmaker Novartis that offer the insurers rebates tied to how well a pricey new heart failure drug works to cut hospitalizations and deaths.
2/29/2016 12:00 pm
(StreetInsider) Feb 29, 2016 - Provectus Biopharmaceuticals, Inc. today announced that it is initiating a protocol titled, “A Phase 1 Study to Assess the Safety, Tolerability and Effectiveness of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver in the Reduction of Biochemical Markers and Symptoms Caused by Secretory Products.”
2/25/2016 11:47 am
(Yahoo! Finance) Feb 25, 2016 - Seattle Genetics, Inc. today announced initiation of a phase 1 clinical trial of SGN-CD19B for relapsed or refractory patients with two subtypes of B-cell non-Hodgkin lymphoma (NHL): diffuse large B-cell lymphoma (DLBCL) and grade 3 follicular lymphoma.
2/24/2016 11:48 am
(Yahoo! Finance) Feb 24, 2016 - Juno Therapeutics, Inc., a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, and Fred Hutchinson Cancer Research Center (Fred Hutch) today announced the creation of a new, best-in-class clinical trials unit (CTU) dedicated to immuno-oncology.
2/22/2016 11:42 am
(Morningstar) Feb 22, 2016 - Seattle Genetics, Inc. today announced initiation of a phase 1/2 clinical trial of vadastuximab talirine (SGN-CD33A; 33A) in combination with azacitidine (Vidaza) in patients with previously untreated myelodysplastic syndrome (MDS).
2/17/2016 12:03 pm
(Reuters) Feb 17, 2016 - The U.S. Food and Drug Administration has granted breakthrough therapy designation for ocrelizumab (OCREVUS) for treating people with primary progressive multiple sclerosis (PPMS), Swiss drugmaker Roche said on Wednesday.
2/5/2016 12:11 pm
(Seattle Cancer Care Alliance) Feb 3, 2016 - World Cancer Day—Thursday, Feb. 4, 2016—is the web launch of a new global campaign to reduce disparities in breast cancer outcomes for 2.5 million women by 2025.
2/4/2016 12:14 pm
(StreetInsider) Feb 4, 2016 - Seattle Genetics, Inc., today announced that it will receive a one-time $20 million milestone payment under its ADCETRIS (brentuximab vedotin) collaboration with Takeda Pharmaceutical Company Limited (Takeda).
1/27/2016 07:02 am
(Philadelphia Inquirer/HealthDay News) Jan 26, 2016 - Women diagnosed with breast cancer who continue to smoke cigarettes are less likely to survive than those who never smoked or those who quit, new research finds.
1/26/2016 11:02 am
(Medical News Today) Jan 26, 2016 - New research that looks at the long-term effects of chemotherapy on breast cancer survivors finds it weakens parts of the immune system for at least 9 months after treatment. This could leave patients with insufficient resilience to common infections, such as pneumonia and tetanus, even if they were immunized previously, say the researchers.
1/12/2016 12:00 pm
(PharmaTimes [UK]) Jan 12, 2016 - Eisai has submitted an application to market its oncology drug lenvatinib for the treatment of patients with renal cell carcinoma.
1/12/2016 11:05 am
(WDRB 41 Louisville News) Jan 12, 2016 - Agreement will support discovery and development of personalized cancer immunotherapies.
1/12/2016 11:05 am
(Yahoo! Finance) Jan 11, 2016 - Strategic collaboration aims to discover and develop potentially novel antibodies against specified targets for immunotherapy.
1/12/2016 11:05 am
(FORMA) Jan 12, 2016 - FORMA Therapeutics announced today that it has successfully met a third objective under its strategic collaboration agreement with Celgene Corporation, triggering an undisclosed payment from Celgene.
1/12/2016 11:05 am
(Philadelphia Business Journal) Updated Jan 12, 2016 - Independence Blue Cross entered into an agreement with NantHealth to cover next-generation whole genome sequencing for a variety of cancers.
1/12/2016 11:05 am
(HLI) Jan 12, 2016 - Human Longevity, Inc., the genomics-based, technology-driven company, announced today its oncology genomics program, including the development of comprehensive whole germline and tumor genome analysis, as well as tumor and germline exome analysis products.
1/12/2016 11:05 am
(U.S. News & World Report/HealthDay News) Jan 12, 2016 - A cancer diagnosis is costly, and new research suggests that it remains costly even after the disease has been treated.
1/12/2016 11:04 am
(ACP/Annals of Internal Medicine) Jan 12, 2016 - Update of the 2009 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for breast cancer.
1/12/2016 11:04 am
(GUMC) Jan 11, 2016 - Unanimous finding of six research teams on breast cancer screening provided to USPSTF.
1/12/2016 11:04 am
(Yahoo! Finance) Jan 11, 2016 - Komen renews concern over Task Force proposal to raise routine mammography age.
1/12/2016 11:04 am
(Merck) Jan 11, 2016 - Acquisition grows Merck’s oncology pre-clinical pipeline with novel IDO1 and TDO inhibitors.
1/12/2016 11:04 am
(BioLineRx ) Jan 12, 2016 - BioLineRx Ltd. today announced a collaboration with MSD, known as Merck in the US and Canada, to support a Phase 2 study investigating BioLineRx's BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, in patients with metastatic pancreatic cancer.
1/12/2016 06:05 am
(NPR/Shots blog) Jan 11, 2016 - After the public had a chance to comment, the influential U.S. Preventive Services Task Force has finalized their latest breast cancer screening recommendations, reiterating that women ages 50-74 ought to receive a screening mammogram every two years.
1/12/2016 06:04 am
(Washington Post) Jan 11, 2016 - Congress has sided with proponents of earlier screening.
1/11/2016 12:05 pm
(Reuters) Jan 11, 2016 - Novartis AG has struck a $170 million alliance with U.S.-based Surface Oncology as it seeks to boost its portfolio of medicines that help the body's immune system fight cancer.
12/23/2015 10:36 am
(Morningstar) Dec 23, 2015 - Seattle Genetics, Inc. and Bristol-Myers Squibb today announced that the companies have initiated a phase 1/2 clinical trial of ADCETRIS (brentuximab vedotin) in combination with Opdivo (nivolumab) for patients with CD30-expressing relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas (NHL), including diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
12/10/2015 12:05 pm
(Yahoo! Finance) Dec 10, 2015 - Seattle Genetics, Inc. today presented data from an ongoing phase 1 clinical trial evaluating SGN-LIV1A, an antibody-drug conjugate (ADC) in development for patients with LIV-1-expressing metastatic breast cancer (MBC), at the 38th San Antonio Breast Cancer Symposium (SABCS) taking place in San Antonio, Texas, December 8-12, 2015.
12/7/2015 04:57 pm
(StreetInsider) Dec 7, 2015 - Seattle Genetics, Inc. today highlighted data presentations evaluating ADCETRIS (brentuximab vedotin) in frontline non-Hodgkin lymphoma at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida, December 5-8, 2015.
12/7/2015 02:08 pm
(Yahoo! Finance) Dec 7, 2015 - Seattle Genetics, Inc. today highlighted several data presentations at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida, December 5-8, 2015, evaluating ADCETRIS (brentuximab vedotin) as both monotherapy and combination therapy in multiple Hodgkin lymphoma (HL) disease settings.
12/7/2015 02:01 pm
(Stockhouse) Dec 7, 2015 - 33A combination therapy and monotherapy demonstrate encouraging anti-leukemic activity in AML; data highlighted in oral presentations; planning 33a phase 3 trial in older AML patients.
12/6/2015 02:39 pm
(Yahoo! Finance) Dec 6, 2015 - Updated data from phase 1 clinical trials support further clinical evaluation of SGN-CD19A in randomized phase 2 trials: testing novel regimens for frontline and relapsed DLBCL.
11/23/2015 11:39 am
(Yahoo! Finance) Nov 23, 2015 - Seattle Genetics, Inc. today announced initiation of a phase 1/2 clinical trial of SGN-CD33A (vadastuximab talirine) in patients with relapsed or refractory acute myeloid leukemia (AML).
11/6/2015 11:33 am
(Yahoo! Finance) Nov 6, 2015 - Seattle Genetics, Inc. today announced that a record number of abstracts were accepted for presentation at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida, December 5-8, 2015.
6/30/2015 12:01 pm
(Fred Hutch News) June 29, 2015 – Cyrus Ghajar, Ph.D., a metastatic breast cancer researcher at Fred Hutchinson Cancer Research Center, has received a $4.1 million Department of Defense Breast Cancer Research Program (BCRP) “Era of Hope” Scholar Award.
5/12/2015 12:00 pm
(GenomeDx) May 12, 2015 - GenomeDx Biosciences today announced the launch of the Decipher® Genomics Resource Information Database (Decipher GRID™), a clinical genomics data sharing program that unites patient registries from leading cancer centers with GenomeDx's full genome profiling platform.